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Abstract 1 
Objectives: The economic burden of multimorbid ity is considerable. This review analyzed the methods of cost-of-2 
illness (COI) studies and summarized the economic outcomes of multimorbidity.  3 
Methods: A systematic review (2000-2016) was performed, which was registered with Prospero, reported according 4 
to PRISMA, and used a quality checklist adapted for COI studies . The inclusion criteria were peer-reviewed COI 5 
studies on multimorbidity, whereas the exclusion criterion was studies focusing on an index d isease. Extracted data 6 
included the definition, measure, and prevalence of mult imorb idity; the number of included hea lth conditions; the 7 
age of study population; the variables used in the COI methodology; the percentage of multimorb idity vs. total costs; 8 
and the average costs per capita.  9 
Results: Among the 26 included articles, 14 defined mult imorbid ity as a simple coun t of 2 or more conditions. 10 
Methodologies used to derive the costs were markedly d ifferent. Given different healthcare systems, OOP payments 11 
of mult imorbid ity varied across countries . In the 17 and 12 studies with cut-offs of ≥2 and ≥3 condit ions, 12 
respectively, the ratios of multimorbid ity to non-mult imorbid ity costs ranged from 2-16 and 2-10. Among the 10 13 
studies that provided cost breakdowns, studies with and without a societal perspective attributed the largest 14 
percentage of mult imorb idity costs to social care and inpatient care/medicine, respectively. 15 
Conclusion: Multimorbid ity was associated with considerable economic burden . Synthesising the cost of 16 
multimorbidity was  challenging due to multip le definitions of mult imorb idity and heterogeneity in COI methods. 17 
Count method was most popular to define multimorbid ity. There is consistent evidence that multimorbidity was 18 
associated with higher costs .  19 
Words: 250/250 20 
 21 
Key points for decision makers :  22 
1. Despite substantial methodological variations between COI studies, there is consistent evidence of considerable 23 
economic burden associated with multimorb idity. 24 
2. Yet pooling the costs from different studies is impossible given different environments, such as healthcare 25 
systems, period of observation and perspectives.  26 
3. Social care is the most important cost drivers in multimorb idity COI studies with societal perspective while 27 
inpatient care/medicine in studies without societal perspective.  28 
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Background 1 
The term multimorbidity refers to the presence of mult iple concurrent chronic health conditions in one 2 
individual without an index d isease [1]. Regard less of the specific definit ion of multimorbidity adopted, it is 3 
common [2], part icularly in the elderly with prevalence estimates of 65-98% for those aged >65 years  [3-5]. 4 
Additionally, a growing body of evidence has indicated an increasing prevalence of multimorbid ity [6]. In the 5 
Netherlands, Uijen and van de Lisdonk found that the prevalence of people with two or more chronic health 6 
conditions increased from 12.3% to 20.5% in primary care from 1985 to 2005 [7]. In the United States, Ward found 7 
that the prevalence of mult imorb idity increased from 21.8% in 2001 to 25.5% in 2012 using the data from a national 8 
household survey [8, 9]. 9 
Multimorb idity is one of the most problemat ic “chronic health conditions” [10] because of the escalating 10 
prevalence and its far-reaching health consequences. Multimorb idity can have a drastic and lifetime impact, as it is 11 
unlikely to be cured. Additionally, compared to single health conditions, multimorbid ity has been related to poorer 12 
health-related quality of life [11, 12], higher health service utilizat ion [13], and negative occupational consequences 13 
[14], such as productivity loss due to presenteeism (e.g., ‘continuing to work while sick’) and absenteeism. 14 
Moreover, healthcare resource consumption is expected to increase not only because of the accumulation of chronic 15 
health conditions but also because of interactions and synergies among health conditions present within an 16 
individual [15]. Given the concurrent changes in epidemio logy, the use of resources and morb idity -related costs of 17 
multimorbid conditions are likely to undergo enormous changes as well, especially since uniform definit ion and 18 
measure of multimorbid ity have been lacking.  19 
Some researchers have begun to summarize the associations of multimorbidity and costs. Lehnert et al. 20 
reviewed the literature in 2011 which was restricted to studies of older adults only [16]. Sambamoorthi et al. 21 
conducted a narrative expert rev iew which does not meet the criteria for a systematic review, i.e . did not report use 22 
of systematic review methodology, did not describe a study protocol and therefore was not registered on Prospero, 23 
did not include a standardised assessment of study quality, and did not follow guidelines for reporting systematic 24 
reviews (e .g. PRISMA) [17]. Our review meets all of these criteria and we believe it p resents an important and 25 
distinct contribution to this field. Another advantage of this review was providing the breakdown of costs . The aim 26 
of this study was two-fold: we first compiled a general description of COI methods, and we subsequently 27 
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systematically reviewed studies on the costs of multimorbidity, analyzing the different methods used , summarizing 1 
their findings on the economic impact of mult imorbid ity and evaluating the quality of the included COI studies. 2 
 3 
Methods  4 
A literature search was performed in the following electronic databases: PROSPERO, Cochrane Library 5 
(including the HTA Database, DARE and Cochrane Database of Systematic Reviews), Health Economic 6 
Evaluations databases (including the NHS Economic Evaluation Database (NHS EED) and Health Economic 7 
Evaluations Database (HEED)), National Institute for Health and Care Excellence (NICE) Evidence Serv ices, 8 
Google Scholar, Scopus, and PubMed. The search strategy combined key words related to mult imorb idity, 9 
comorbid ity and multip le chronic health conditions. The search was restricted to papers written in English and 10 
published since 2000 up to October 2016. The inclusion criteria were peer-reviewed COI studies (including cross -11 
sectional, cohort and modeling studies); the exclusion criterion was studies focusing on an index d isease. The main 12 
difference between comorb idity and multimorbid ity was whether an index disease was specified or not. Calculating 13 
the costs without distinguishing those two situations may lead to an underestimation of the burden of mult imorb idity. 14 
As in “comorbid ity”, allied treatments of the dominant disease might also apply to the triggered secondary diseases, 15 
while in “mult imorb idity”, each disease receives relatively independent treatments . Therefore, we included 16 
“comorbid ity” in the search terms primarily because of the interchangeable use of the terms “comorbidity” and 17 
“multimorbidity” in the literature. Then, during the article screening stage, studies were excluded if they focused on 18 
“an index disease”. Figure 1 illustrates the literature search and selection process and presents the reasons for study 19 
exclusion. As an example, the search strategy for PubMed is shown below. 20 
(((multimorbid ity[Tit le/Abstract]) OR (multi-morb idity[Title/Abstract]) OR (comorbidity[MeSH Terms]) 21 
OR (co-morbid ity[Tit le/Abstract]) OR ((mult iple[Tit le/Abstract]) AND (chronic[Title/Abstract] OR long -22 
term[Title/Abstract] OR "long term"[Tit le/Abstract]) AND (illnesses[Title/Abstract] OR diseases[Title/Abstract] 23 
OR conditions[Title/Abstract]))) AND ((forecasting[MeSH Terms]) OR (health expenditures[MeSH Terms]) OR 24 
(spending[Title/Abstract]) OR (costs and cost analysis[MeSH Terms]) OR (cost -of-illness[Title/Abstract]) OR (cost 25 
of illness[Title/Abstract])) AND English[Language] AND ("2000"[Date - Publicat ion] : "3000"[Date - Publication])) 26 
NOT (letter[Publication Type] OR news[Publication Type] OR editorial[Publicat ion Type] OR “newspaper 27 
article”[Publication Type] OR comment[Publication Type]) . 28 
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All t itles and abstracts were screened by two independent reviewers  (LLW and LS), after which the full 1 
texts of all potentially elig ible papers were obtained and screened by  the same two rev iewers. For any disagreement, 2 
the abstract was set aside for further evaluation. After a consensus was reached on the final sample o f papers, the 3 
primary reviewer (LLW) screened the reference lists of the included papers for additional papers that fulfilled the 4 
inclusion criteria. This review was reported in accordance with the Preferred Reporting Items for Systematic 5 
Reviews and Meta-Analyses (PRISMA) guidelines [19]. 6 
Formal international guidelines for quality analyses of COI studies are lacking; therefore, relevant 7 
informat ion was extracted referring to the British Medical Journal Checklist  [20] for economic submissions and was 8 
adapted for COI studies by Molinier et al. [21]. Equal weight was assigned to each item of the checklist, and the 9 
final score was the sum of the 10 individual items. The two reviewers assessed each study separately. If there was 10 
disagreement between two reviewers at this stage, the paper was discussed with reference to the aforementioned 11 
COI study checklist until agreement was reached.  12 
This systematic review summarized the results referring to the items of COI methods, which have been 13 
described elsewhere [18, 20, 21]. The items included the definit ion of multimorbidity, the epidemiological approach, 14 
the perspective of the study and the type of costs assessed, resource consumption and unit costs, and sensitivity 15 
analyses (dimensions shown in Table 1and Table 2). 16 
Investigating subgroup heterogeneity in COI estimates represents  an area for future research [22]. 17 
Therefore, the included studies had to be stratified and presented by different components of costs , with clear 18 
explanations of the groups. To make the costs comparable, cost estimates were all converted to USD ($), accord ing 19 
to the 2016 exchange rate for each study and each currency, with adjustments over time based on the Consumer 20 
Price Index (CPI) for the original currency. Costs were reported as average annual costs (per-capita costs) unless 21 
stated otherwise, because the total costs reported in the different studies varied depending on the included sample 22 
sizes. The results were synthesized descriptively.  23 
 24 
Results  25 
A total of 7,249 studies were identified from the PubMed and Scopus literature search. After the titles, 26 
abstracts and full text  were screened, 19 studies remained. Then, we incorporated three studies from other databases 27 
that were not identified from PubMed and Scopus. With these 22 studies, we screened the references and identified 28 
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four studies that had not been identified in our literature search. Finally, twenty-six studies met our criteria (shown 1 
in Tables 1-3). The years of valuation ranged from 1996 to 2013. Thirteen studies were conducted in the United 2 
States [23, 24, 3, 25-34], seven in Europe [13, 35-40], two in Australia [41], one each from Canada [42], Singapore 3 
[43] and Taiwan [44], and two in middle- or low-income regions [40, 45]. Overall, twenty studies used a prevalence 4 
approach [23, 24, 3, 25-28, 13, 35, 30, 31, 41, 37, 38, 45, 39, 46, 40, 32, 43], seven used an incidence approach [36, 5 
29, 44, 42, 33, 34, 27], and only one used an economic model to estimate the lifet ime costs of mult imorb idity [36]. 6 
The studies analyzed samples ranging in size from 1,252 to 292 million [28]. Twenty-five studies specified the age 7 
range of the sample [26]. Twenty-one studies calculated estimates in a population 65 years and older [23, 24, 3, 25, 8 
27, 28, 13, 35, 36, 44, 30, 31, 41, 37, 38, 45, 39, 46, 40, 32, 43], eight studies included people under 18 years old 9 
[23-25, 28, 36, 44, 30, 38], and three studies were conducted in children only [42, 33, 34]. The average annual cost 10 
of mult imorbid ity per capita ranged from $49 [40] to $252,313 [33], showing significant variation by study. 11 
Additionally, out-of-pocket (OOP) expenditures ranged from $49 [40] to $6,858 [27], which was lower than public 12 
insurance costs. Children with three or more life-threatening complex chronic conditions in their last year of life had 13 
the highest costs ($252,313) [33].  14 
 15 
Identifying multimorbidity 16 
In total, fourteen studies provided the same, clear defin ition of mult imorbid ity, i.e., the ≥2 simple count 17 
method [23, 13, 29, 35, 30, 31, 41, 37, 38, 45, 39, 40, 32, 43]. Twelve studies estimated the costs by number, 18 
including five “organ system” and seven “health condition or symptom” studies, although they did not refer to the 19 
term “mult imorb idity”. For other defin itions of mult imorb idity, COI information was very limited. Only four studies 20 
accounted for the severity of health conditions when measuring multimorbidity; two of them used the Cumulat ive 21 
Illness Rating Scale (CIRS) [35, 37]; the Clin ical Risk Groups (CRG) model [36] and Rx-defined morb idity groups 22 
(Rx-MG) [44] were each used only once. The number of health conditions included when identifying 23 
multimorbidity ranged from 4 [32] to 259 [23, 26, 29].  24 
 25 
Epidemiological approach 26 
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Six studies followed an incidence-based approach [27, 29, 36, 44, 42, 33, 34], and twenty studies calculated 1 
prevalence-based healthcare costs  [23, 24, 3, 25-28, 13, 35, 30, 31, 41, 37, 38, 45, 39, 46, 40, 32, 43]. Lifetime costs 2 
were estimated in only one study [36], and unfortunately, specific multimorbid ity-related costs were unavailable.  3 
 4 
Perspective of the analysis and costs assessed 5 
Three perspectives were included: eighteen studies were from the payer’s perspective [23, 24, 3, 25-29, 36, 6 
44, 30, 31, 41, 45, 39, 46, 40, 34], six were from healthcare providers’ perspective [13, 35, 38, 32, 33, 42], and two 7 
used the societal perspective [37, 43]. However, both of the studies from the societal perspective defined costs as 8 
including only healthcare and social care costs. Twelve studies included both medical and non-medical expenditures 9 
when quantifying direct costs  [23, 24, 3, 27, 28, 31, 41, 37, 46, 40, 32, 43]. 10 
 11 
Estimating resource consumption 12 
Three approaches can be used to estimate resource consumption: bottom-up, top-down and econometric 13 
[47]. While the top-down approach typically requires cost data as well as relative risks to calculate population -14 
attributable fractions, the bottom-up approach often requires data from multip le sources, and the econometric 15 
approach often requires only a single dataset [47]. Sixteen studies gathered data on resource consumption from 16 
different departments (bottom-up approach) [3, 25, 26, 13, 29, 35, 36, 44, 30, 31, 37, 38, 32, 42, 33, 34]. One used a 17 
combined bottom-up and top-down approach [35]. Ten studies extracted costs from the single database, called an 18 
econometric approach [23, 24, 27, 28, 41, 45, 39, 46, 40, 43]. The follow-up periods included lifet ime follow-up in a 19 
study that adopted an incidence-based approach [36], six years in one study [44], four years in three studies [29, 33, 20 
34] and two years in one study [42]. 21 
 22 
Valuation of unit costs  23 
Sources of cost estimations  24 
Most American studies calculated costs from Medicare payments and the Medical Expenditure Panel 25 
Survey (MEPS), which provided national, continuous and comparable estimates over time. An Irish study used data 26 
from primary care consultations  and outpatient and inpatient visits extracted from family practices [13]. One study 27 
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quantified indirect costs  [43]. Four studies did not provide the unit costs  [25, 38, 36], and one study reported the 1 
unit incremental cost only [37].  2 
Discounting costs 3 
Studies with time horizon less than one or two years did not normally discount costs. In all included studies 4 
in this review, costs were not discounted, even in the longitudinal studies with more than a two-year follow-up. 5 
 6 
Sensitivity analysis 7 
None of the studies analyzed or discussed the variables that had a significant impact on cost estimates. 8 
 9 
Presentation of results  10 
The results were clearly presented in most studies and were mainly well explained and consistently 11 
reported in relation to the methods adopted. Three studies did not differentiate costs . Based on the key 12 
methodological points, a checklist of questions was used with fu ll exp lanations given for clarity  (Table 3). For 13 
fourteen studies, the answer to seven of ten questions was “yes”, and all the studies were scored “no” on question 9 14 
“Were the major assumptions tested in a sensitivity analysis?” Questions 3 “Were direct/indirect costs sufficiently 15 
disaggregated?” and 7 “Were unit costs appropriately valued?” received fewer “yes” answers than the other 16 
questions. In one American study [24], the costs were sufficiently d isaggregated only for single conditions , and the 17 
costs of mult imorbid ity were presented only as additional or supplementary in formation.  18 
 19 
Discussion 20 
We systematically reviewed 26 COI studies on multimorb idity without restricting the studies to any 21 
specific definition of mult imorbid ity, and this broad inclusion contributed to a comprehensive understanding of 22 
multimorbidity and its economic burden. The costs of multimorbidity ranged from $49 [40] to $252,313 [33] annual 23 
per capita and increased according to the level of multimorb idity within each study. We found a relative paucity of 24 
data on the costs of multimorbid ity, but the available data still provided valuable information for us to better 25 
elucidate the current magnitude of the economic burden of multimorbidity. Methods were highly heterogeneous 26 
producing a wide range of COI estimates . Even at the lower bounds, these costs were substantial.  27 
 28 
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Costly multimorbidity 1 
The proportion of costs due to mult imorb idity in relat ion to the total costs ranged from 3.4 to 97.8%. Most 2 
(n=18) estimates were 60% and above. One study with an extraord inarily low estimate (3.4%) [46], which seemed 3 
inconsistent with the other studies, only evaluated three-month cases of out-of-pocket (OOP) expenditures in 4 
Australia. Two factors could explain this finding. First, the respondents had a 17% higher average income than the 5 
Australian general population [46] and thus underrepresented lower socioeconomic groups (including the indigenous 6 
population), who are most likely to experience higher cost burdens. Second, the conditions included in the study 7 
were all chronic, which required ongoing treatment [48], and the short duration of the study may not have reflected 8 
all incurred costs.  9 
The highest costs of mult imorbid ity per person occurred in the last year of life among child ren with life -10 
threatening conditions ($252,313) [33]. The costs in all three studies with young respondents ranged from $8,551 11 
[34] to $252,313 [33] and did not include direct non-medical or indirect costs . Although the childhood prevalence 12 
estimates of chronic health conditions ranged from 0.22% to 44% [49], which was much lower than the 12.9% to 13 
95.1% prevalence of mult imorbid ity in the broader age groups [50], multimorbid ch ildren and their families still 14 
faced substantial financial pressure. Moreover, the included studies indicated a persistence of high costs in the 15 
following years.  16 
 17 
Heterogeneity of multimorbidity COI studies 18 
Three relevant perspectives of the costs of mult imorb idity were included. The societal perspective, 19 
including care costs, was used in two studies, but they did not account for the costs of productivity loss  due to 20 
multimorbidity [51], including presenteeism, absenteeism, premature retirement and death, which are responsible for 21 
a substantial proportion of the financial burden [52]. Information about productivity loss, premature ret irement and 22 
death could be derived from the working population. Only one Australian study in this review was conducted among 23 
working-age adults and included those who were not in the workforce [29]. Unemployed populations are more likely 24 
to have more chronic conditions than employed groups [51]. However, that study did not estimate productivity loss, 25 
which could have been addressed with the available data.  26 
Six studies adopted a cohort study design, with follow-up periods ranging from two to six years. The 27 
remain ing twenty studies used cross-sectional data, which reflect only the time of data collection and are limited in 28 
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their ability to draw valid conclusions about associations or possible causality [53]. Compared to other reviews of 1 
COI studies on a specific single disease, this review on mult imorb idity included fewer cohort studies [54]. Data 2 
collection over a long period of t ime is difficu lt and time- and cost-intensive; however, modeling designs could 3 
compensate for these challenges [55]. In this review, on ly Carreras et al. simulated indiv idual costs until death using 4 
a stationary Markov chain under the assumption that transition probabilities were constant [36]. This approach was 5 
not consistent with the nature of chronic conditions, in which health states change dynamically, and modeling of 6 
chronic conditions should consider this difference [55]. However, the lifetime mult imorb idity costs could be 7 
reasonably predicted in this regional study. 8 
Several studies did not fully describe their methods and were thus difficult to assess. This ambiguity might 9 
be due to a general lack of economic awareness in the medical journals that support economic studies. A 10 
community-based cohort ensures a more representative patient population, but the diagnosis of this cohort may rely 11 
on self-reported data, which are certain ly less precise. The studies analyzed here confirm that multimorb idity is 12 
costly and suggest that the costs of mult imorb idity account for a large share of the total costs (Table 2). 13 
Given different healthcare systems, OOP payments varied across countries , but OOP expenditure of 14 
multimorbidity is always greater than that of non-mult imorb idity. For example, in China, the patients with 15 
multimorbidity have higher OOP expenditure than those without multimorbid ity , even among those with health 16 
insurance [40]. Find ings from economic studies in different countries or regions cannot be easily generalized due to 17 
monetary issues; for example, d ifferent currencies have different purchasing power for the same product [57]. 18 
 19 
Definitions of multimorbidity 20 
It is well known that there is no singular definit ion of multimorbidity, and the two cut-off count method is 21 
generally the most broadly accepted definition used. In this review, we found that all the COI studies that provided a 22 
definit ion of mult imorb idity adopted only this method. Most of the studies that did not specifically define 23 
multimorbidity also presented costs by the number of multimorbid conditions. Using the same definit ion increased 24 
the comparability within the available  COI studies.  25 
The number of included health conditions used to identify multimorbidity ranged from 4, which were 26 
highly prevalent, disabling or expensive conditions in an American community [32], to 259, which included all 27 
conditions in clinical classification systems [29]. The costs did not increase as more condit ions were included. The 28 
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wide variation in severity within specific  conditions [56] could produce different costs . For example, children with 1 
life-threatening conditions had the highest healthcare expenditure in this review [33].  2 
Using the two cut-off count method to define mult imorb idity, the ratios of the costs of multimorbid ity to 3 
non-mult imorbid ity ranged from 2 to 16, while the rat ios ranged from 2 to 10 using the three cut-off count method. 4 
Nevertheless, interpreting these quantitative results is problematic because of the different approaches used. 5 
Domestic characteristics with in each country or region, such as clin ical pract ice settings and healthcare systems, also 6 
affect resource consumption and unit costs. For example, medication costs can vary among studies because of the 7 
use of tariffs in solidarity systems, which are not comparable to free prices in private systems. 8 
The different methodologies used to identify mult imorb idity led to the wide range in expenditures reported 9 
above. The number and diversity of available studies on multimorbid ity provide an insufficient scientific basis for 10 
further exp lorations on mult imorb idity. Therefore, it is vital to improve the methodological quality of 11 
multimorbidity COI research to gain a better understanding of this common and important phenomenon. Moreover, 12 
further research is needed to clarify the costs of mult imorb idity from the societal perspective.  13 
 14 
Limitations and strengths 15 
The results of this review are limited by the nature of the studies identified. The main limitat ion of this 16 
review is its inability to include all relevant studies. Costs were estimated in 16 countries or regions from 1996 to 17 
2013. The large number of abstracts derived from the databases improved the sensitivity of our search strategy. The 18 
absence of a MeSH term for multimorbidity is a clear limitation. However, adding mult imorb idity-related terms 19 
from prev ious studies to our search strategy helped circumvent this limitation. We included papers published in 20 
English only, which restricted our sample  to some extent. The OOP can vary widely between countries because of 21 
different health insurance systems and types of diseases, therefore, we have only reported the range of OOP payment 22 
in different countries. Based on the fact that mult imorbid ity is not prevalent in the young population, the pediatric 23 
multimorbidity studies were rare, therefore, the costs of multimorbidity could not be distinguished by age and the 24 
finding of pediatric studies in this review was limited. 25 
Moreover, the practicality of COI studies themselves in aiding policy decision-making has been debated 26 
[58, 59], and their inability to priorit ize resources has been criticized as well [60, 61]. COI studies, which aim to 27 
identify and measure all costs of health condition serve a different purpose than other health economic evaluations 28 
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(e.g., cost-benefit, cost-effectiveness, and cost-utility analyses), which aim to assess both costs and outcomes of the 1 
adopted intervention/policy [62-64]. However, COI studies can provide useful informat ion as long as they adhere to 2 
standardized and acceptable methodologies [65, 66]. Furthermore, the results of COI studies have been used by 3 
organizations such as the World Bank and the World Health Organizat ion to estimate public, private and total 4 
national health expenditures globally [67]. Different stakeholders can utilize COI studies for different purposes [68]. 5 
For example, governments can estimate the financial impact of a disease on public budgets for resource allocation 6 
purposes, whereas pharmaceutical corporations can identify diseases with high management costs and direct 7 
research and development investments accordingly. However, caution is warranted when using COI studies; for 8 
optimal resource allocation, they should be used in combination with other thorough economic evaluations [69]. 9 
Despite these limitations, this review provides an overview of the range of es timates reported in recent 10 
decades, and the collated evidence provides a greater understanding of the COI of multimorbidity than the results 11 
provided by individual studies. Moreover, this review adds systematic evidence about the methodologies used to 12 
analyze multimorbidity costs and provides insight into the reasons for the disparate results among studies. Although 13 
multimorbidity complicates the findings of COI studies, this review can be useful for informing decisions about the 14 
prioritization of resources [70, 71], particu larly when combined with other economic assessments. 15 
 16 
Conclusion  17 
Noting the substantial methodological variat ions between studies, multimorbid ity was associated with a 18 
considerable economic burden. Although this review identified two studies estimating the costs from a societal 19 
perspective, there was a consistent theme throughout the included studies that those with mult imorbid ity had higher 20 
costs than those without multimorbidity. Future research should focus on improving the methods of estimating costs . 21 
A closer agreement of defin ition of multimorbid ity is still required to allow consistent comparisons and enhance the 22 
interpretation of study findings among future studies.  23 
 24 
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Figure 1. Flowchart illustrating the search process 1 
 2 
  3 
Articles excluded due to index disease 
(n=11) 
PubMed search (n=2,583) 
Scopus search (n=4,666) 
Duplicates (n=1,565) 
Articles retrieved (n=5,684) 
Articles excluded after screening of title and 
abstract (n=5,654) 
Articles retrieved and 
reviewed in full text (n=30) 
With PROSPERO, Cochrane Library 
(including HTA-Health Technology 
Assessment Database, DARE-Database of 
Abstracts of Reviews of Effects and 
Cochrane Database of Systematic Reviews), 
Health Economic Evaluations databases, 
National Institute for Health and Care 
Excellence (NICE) Evidence Services, 
Google Scholar, additional articles (retrieved 
and reviewed in full text) were not already 
identified by the PubMed & Scopus search 
(n=3) 
 
Additional articles (retrieved and reviewed 
in full text) from the references of 23 articles 
which were not already identified by the 
searches above (n=4) 
Included Articles (n=26), of which n = 19 are from PubMed & Scopus, n=3 are 
additional articles search not from PubMed & Scopus, and n=4 are from references 
search 
Articles retrieved (n=22) 
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Table 1. Methodology of included cost-of-illness studies in multimorbidity 
Study Country Perspective  Epidemiological approach Study design Year of  valuation Currency 
Hwang et. al [23] USA Payer (OOP) Prevalence Cross-sectional 1996 USD 
Garis et. al [24] USA Payer (public insurance) Prevalence Cross-sectional 1995 USD 
Wolff et. al [3]  USA Payer (public insurance) Prevalence Cross-sectional 1999 USD 
Anderson et. al [25] USA Payer (public insurance) Prevalence Cross-sectional 1998 USD 
Thorpe et. al [26] USA Payer (public insurance) Prevalence Cross-sectional 1987 USD 
Thorpe et. al [26] USA Payer (public insurance) Prevalence Cross-sectional 1997 USD 
Thorpe et. al [26] USA Payer (public insurance) Prevalence Cross-sectional 2002 USD 
Schoenberg et. al [27] USA payer (OOP) Prevalence/incidence Cross-sectional 1998 USD 
Schoenberg et. al [27] USA Payer (OOP) Prevalence/incidence Cross-sectional 2002 USD 
Paez et. al [28] USA Payer (OOP) Prevalence Cross-sectional 2005 USD 
Glynn et. al [13] West of Ireland (national representative) Health care providers Prevalence Cross-sectional 2009 EUR 
Naessens et. al [29] USA Payer Incidence Cohort (4 years follow-up) 2007 USD 
Nagl et. al [35] Germany  Health care providers Prevalence Cross-sectional 2010 EUR 
Carreras et. al [36] the county of Baix E mpordà in Catalonia (Spain) Payer (public insurance) Incidence cohort (lifetime)  2007 EUR 
Kuo et. al [44] Taiwan payer (public insurance) Incidence Cohort (6 years follow-up) 2010 USD 
Lochner et. al [30] USA Payer (public insurance) Prevalence Cross-sectional 2011 USD 
Machlin et. al [31] USA Payer (public insurance) Prevalence Cross-sectional 2009 USD 
McRae et.  al [41] Australia Payer (public insurance) Prevalence Cross-sectional 2009 AUD 
Heider et. al [37] Germany  Payer (OOP) Prevalence Cross-sectional 2009 EUR 
Orueta et. al [38] Basque country (region in Spain/France) Societal Prevalence Cross-sectional 2011 EUR 
Pati et. al [45] India Health care providers Prevalence Cross-sectional 2007 INR 
Bahler et. al [39] Switzerland Payer Prevalence Cross-sectional 2013 Swiss francs 
Lee et. al [40] China Payer (OOP) Prevalence Cross-sectional 2010 CNY 
Lee et. al [40] Ghana Payer (OOP) Prevalence Cross-sectional 2010 GHC 
Lee et. al [40] Mexico  Payer (OOP) Prevalence Cross-sectional 2010 INR 
Lee et. al [40] Russia Payer (OOP) Prevalence Cross-sectional 2010 MXN  
Lee et. al [40] South Africa Payer (OOP) Prevalence Cross-sectional 2010 RUB 
Lee et. al [40] India payer (OOP) Prevalence Cross-sectional 2010 ZAR 
Meraya et. al [32]  USA health care providers & payer Prevalence Cross-sectional 2011 USD 
Picco et. al [43] Singapore societal Prevalence Cross-sectional 2013 SGD 
Carpenter et. al [46] Australia payer (OOP) Prevalence Cross-sectional 2009 USD 
Cohen et. al [42] Canada health care providers Incidence Cohort (2 years follow-up) 2005-2007 CAD 
Ananth et. al [33] USA health care providers Incidence Cohort (4 years follow-up) 2012 USD 
Zhong et. al [34] USA payer (public insurance) Incidence Cohort (4 years follow-up) 2004 USD 
 
OOP, out-of-pocket; USA, United States of America; USD, United States Dollar; EUR, Euro; AUD, Australian Dollar; INR, Indian Rupee; CNY, Chinese Yuan; GHC, Ghana Cedi; MXN, Mexican 
Peso; RUB, Russian Rouble; ZAR, South African Rand; SGD, Singapore Dollar; CAD, Canadian Dollar.  
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Table 2. The definition, measure, costs of multimorbidity 
Study 
Def inition of
 MM 
Measure of  MM 
Number of  included c
onditions 
Age range
 (y.o.)  
Prevalence of  MM 
(%) 
%(MM) of  t
otal costs 
Direct costs  Average costs of  MM ($)*  MM/non-MM 
Direct me
dical costs 
Direct non-me
dical costs 
Indirect
 costs 
MM2+  MM3+  MM2+  MM3+  
Hwang et. al [23] MM2+ Count 259 0-80+ 17.0 38.1 yes no no 1387 1733.0 3 3 
Garis et. al [24] NS Count 9 0+ NA NA yes yes no 7938 NA NA NA 
Wolff et. al [3]  NS ACG 3493 65+ 65(MM2+)/43(MM3+) 95.3 yes yes no 10627 14276.0 11 10 
Anderson et. al [25] NS Count NS 0+ NA NA yes no no NA NA NA NA 
Thorpe et. al [26] NS Count 259 NS 76.4 92.2 yes no no 13330 14989.8 6 3 
Thorpe et. al [26] NS Count 259 NS 80.5 95.1 yes no no 10950 12158.8 5 4 
Thorpe et. al [26] NS Count 259 NS 86.2 97.2 yes no no 11666 12864.0 6 5 
Schoenberg et. al [27] NS Count 8 65+ 58.1 70.6 yes yes no 3858 4109.0 2 2 
Schoenberg et. al [27] NS Count 8 65+ 70.4 78.6 yes yes no 6856 7687.6 2 2 
Paez et. al [28] NS Count NS 0+ 24(MM2+)/13(MM3+) 48.5 yes yes no 1844 2306.0 16 4 
Glynn et. al [13] MM2+ Count 147 50+ 66.2 82.5 yes no no 2211 2602.0 2 2 
Naessens et. al [29] MM2+ Count 259 18-64 54.3 82.5 yes no no 13285 16245.0 4 4 
Nagl et. al [35] MM2+ CIRS 33 65+ 86.4 94.8 yes no no 3778 4422.0 2 2 
Carreras et. al [36] NS CRG model 
all 857,385 ICD codes 
(815,227 diagnostics a
nd 42,158 procedures) 
0+ 17.8 NA yes no no NA NA NA NA 
Kuo et. al [44] 
NS counting the numb
er of Rx-MG  
55 0-71 80 
NA yes 
no no 1045 NA 4 NA 
Lochner et. al [30] MM2+ Count 15 0+ 67.3 92.6 yes no no 13949 NA 6 NA 
Machlin et. al [31] MM2+ Count 20 18+ 25.0 60.3 yes yes no 11934 NA 4 NA 
McRae et.  al [41] MM2+ Count 6 50+ 55.8 81.0 yes yes no 1781 2014 2 2 
Heider et. al [37] MM2+ CIRS-G  14 57-84 NA 74.0 yes yes no NA NA NA NA 
Orueta et. al [38] MM2+ ACG 52 0+ 23.6 63.6 yes no no NA NA NA NA 
Pati et. al [45] MM2+ Count NS 18+ 1.3-30.6 NA yes no no 240 NA NA NA 
Bahler et. al [39] MM2+ Count 22 65+ 76.6 94.7 yes no no 8233 NA 5 NA 
Lee et. al [40] MM2+ Count 9 18+ 
1.4% in 18–29 years ol
d to 40.0% in those age
d 70+ years 
NA yes yes no 655 NA NA NA 
Lee et. al [40] MM2+ Count 9 18+ NA yes yes no 92 NA NA NA 
Lee et. al [40] MM2+ Count 9 18+ NA yes yes no 165 NA NA NA 
Lee et. al [40] MM2+ Count 9 18+ NA yes yes no 151 NA NA NA 
Lee et. al [40] MM2+ Count 9 18+ NA yes yes no 49 NA NA NA 
Lee et. al [40] MM2+ Count 9 18+ NA yes yes no 60 NA NA NA 
Meraya et. al [32]  MM2+ Count 4 21+ 100.0 NA yes yes no 12317 16454 NA NA 
Picco et. al [43] MM2+ Count 10 60+ 51.5 80.7 yes yes no 11167 NA 2 NA 
Carpenter et. al [46] NS Count 11 50+ 71.1 3.4 yes yes no 4447 3415 3 2 
Cohen et. al [42] NS Count 9 organ systems 0-16 6.7 NA yes no no 36434 NA NA NA 
Ananth et. al [33] NS Count 9 organ systems 0-17 66.1 88.59 yes no no 252313 360046 4 4 
Zhong et. al [34] NS Count 20 1-19 17 44.84 yes no no 8551 15797 4 6 
 
*All costs are in $ (1 EUR=1.0886 USD;1 AUD=0.762966 USD;1 INR=0.014948 USD;1 CHF=1.005635 USD;1 CNY=0.143719 USD;1 MXN=0.049 118 USD;1 RUB=0.016234 USD;1 
ZAR=0.071561 USD;1 SGD=0.717926 USD; December 18, 2016). 
ACG, Adjusted Clinical Groups; Rx-MG, Rx-defined morbidity groups; CRG, Clinical Risk Groups; CIRS, Cumulative Illness Rating Scale; CIRS-G, Cumulative Illness Rating Scale for Geriatrics; 
ICD, the International Classification of Diseases; MM, multimorbidity; MM2+, two-cutoff count method of multimorbidity; MM3+, three-cutoff count method of multimorbidity; y.o., years old; NS, not 
specific; NA, not available.  
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Table 3. Ans wers to the methodological questions by study 
Questions/answers 
All 
studies 
Hwang 
et. al 
[23] 
Garis 
et. al 
[24]  
Wolff 
et. al 
[3] 
Anderson 
et. al [25] 
Thorpe 
et. al 
[26] 
Schoenberg 
et. al [27] 
Paez 
et. al 
[28] 
Glynn 
et. al 
[13] 
Naessens 
et. al [29] 
Nagl 
et. al 
[35] 
Carreras 
et. al [36] 
Kuo et. 
al [44] 
Lochner 
et. al [30] 
Machlin 
et. al [31] 
1 Was a clear def inition of  the illness given?  1 p p 0 p p 0 1 1 1 p p 1 1 
2 Were epidemiological sources carefully described?  1 1 1 P 0 1 1 1 0 1 p 1 1 1 
3 Were direct/indirect costs suff iciently disaggregated?  1 0 0 0 0 0 1 1 0 1 0 0 0 0 
4 Were activity data sources carefully described?   1 1 1 1 1 1 1 1 0 p p 1 1 p 
5 Were activity data appropriately assessed?  1 1 1 0 p 1 1 1 p 1 1 1 1 p 
6 Were the sources of  all cost values analytically described?  1 0 0 0 1 1 1 1 0 1 1 1 p 0 
7 Were unit  costs appropriately valued?   1 1 1 1 1 1 1 1 1 1 p 1 1 1 
8 Were the methods adopted carefully explained?  p 1 1 p p 1 1 1 0 1 1 1 p p 
9 Were the major assumptions tested in a sensitivity analysis?  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
10 Was the presentation of  study results consistent with the 
methodology of  the study?  
 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
                
Total score by study                
YES(1)  166 8 6 6 3 3 7 8 9 3 8 5 7 6 4 
NO(0) 58 1 3 3 5 3 2 2 1 6 1 2 2 2 3 
PARTIALLY(p)  37 1 1 1 2 4 1 0 0 1 1 3 1 2 3 
 
Table 3. (Continuous) 
Questions/answers 
All 
studies 
McRae 
et. al 
[41] 
Heider 
et. al 
[37] 
Orueta 
et. al 
[38] 
Pati 
et. al 
[45] 
Bahler 
et. al 
[39] 
Lee 
et. al 
[40] 
Meraya 
et. al 
[32] 
P icco 
et. al 
[43] 
Carpenter 
et. al [46] 
Cohen 
et. al 
[42] 
Ananth 
et. al 
[33] 
Zhong 
et. al 
[34] 
1 Was a clear def inition of  the illness given?  1 1 1 p 1 1 1 1 p p p p 
2 Were epidemiological sources carefully described?  1 1 1 1 1 p 1 1 1 1 1 1 
3 Were direct/indirect costs suff iciently disaggregated?  0 p 1 1 1 1 0 1 1 0 0 0 
4 Were activity data sources carefully described?   1 1 1 1 1 1 p p 1 1 1 p 
5 Were activity data appropriately assessed?  1 1 1 1 1 1 1 1 1 1 1 p 
6 Were the sources of  all cost values analytically described?  1 p 1 p 1 1 0 1 1 p 1 1 
7 Were unit  costs appropriately valued?   1 1 1 0 0 0 0 1 1 1 1 1 
8 Were the methods adopted carefully explained?  1 1 p 1 1 p 1 1 1 1 1 1 
9 Were the major assumptions tested in a sensitivity analysis?  0 0 0 0 0 0 0 0 0 0 0 0 
10 Was the presentation of  study results consistent with the methodology 
of  the study? 
 1 1 1 1 1 1 1 1 1 1 1 1 
              
Total score by study              
YES(1)  166 8 7 8 6 8 6 5 8 8 6 7 6 
NO(0) 58 2 1 1 2 2 2 4 1 1 2 2 2 
PARTIALLY(p)  37 0     3 1      
 
Total score by study is the sum of answers. P, partially.  
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